Publicacions en col·laboració amb investigadors/es de Hospital Universitario Virgen del Rocío (156)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  2. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection

  3. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

    Bone Marrow Transplantation

  4. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics

  5. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

  6. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

    Hematological Oncology, Vol. 42, Núm. 1

2023

  1. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

    International Journal of Infectious Diseases, Vol. 137, pp. 98-110

  2. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

    Haematologica, Vol. 108, Núm. 1, pp. 22-33

  3. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  4. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  5. Durable ventricular assist device in Spain (2007-2020). First report of the REGALAD registry

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 227-237

  6. Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials

    Haematologica, Vol. 108, Núm. 4, pp. 969-980

  7. Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study

    Blood Cancer Journal, Vol. 13, Núm. 1

  8. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

    HemaSphere

  9. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

    Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655

  10. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  11. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

    Haematologica

  12. Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil

    Cancers, Vol. 15, Núm. 5

  13. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO

    British Journal of Haematology, Vol. 203, Núm. 2, pp. 202-211

  14. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

    eClinicalMedicine, Vol. 58